Irenic Capital Management LP Invests $1.62 Million in Atea Pharmaceuticals, Inc. $AVIR

Posted by Stanley Muller on Jul 29th, 2026

Irenic Capital Management LP purchased a new position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 301,699 shares of the company’s stock, valued at approximately $1,623,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Prudential Financial Inc. purchased a new position in Atea Pharmaceuticals during the 2nd quarter valued at $36,000. RFG Advisory LLC purchased a new stake in Atea Pharmaceuticals in the fourth quarter worth $53,000. BNP Paribas Financial Markets increased its stake in Atea Pharmaceuticals by 57.7% in the third quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company’s stock worth $58,000 after purchasing an additional 7,286 shares during the period. Jump Financial LLC increased its stake in Atea Pharmaceuticals by 36.5% in the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock worth $68,000 after purchasing an additional 5,106 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Atea Pharmaceuticals during the fourth quarter worth $69,000. 86.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Analysis on Atea Pharmaceuticals

Atea Pharmaceuticals Price Performance

Shares of AVIR stock opened at $4.51 on Wednesday. The company has a market capitalization of $360.94 million, a P/E ratio of -2.14 and a beta of 0.31. The company’s 50-day simple moving average is $4.57 and its two-hundred day simple moving average is $4.80. Atea Pharmaceuticals, Inc. has a one year low of $2.78 and a one year high of $6.45.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. On average, research analysts expect that Atea Pharmaceuticals, Inc. will post -1.93 EPS for the current fiscal year.

Atea Pharmaceuticals Company Profile

(Free Report)

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.